A pioneer in the Prostate Cancer Therapy
Famous Greeks

A pioneer in the Prostate Cancer Therapy

Dr. Christopher J. Logothetis is internationally recognized for his research in prostate cancer, with new combinations of cytotoxic drugs and preoperative gene therapy.

Dr. Christopher J. Logothetis is Department Chair and Professor of the Genitourinary Medical Oncology Division of Cancer Medicine at The University of Texas M. D. Anderson Cancer Center in Houston, the Roy M. and Phyllis Gough Huffington Clinical Research in Urologic Oncology Distinguished Chair and Director of the David H. Koch Center for Applied Research of Genitourinary Cancers at M. D. Anderson Cancer Center. He is also the Principal Investigator of the M. D. Anderson Cancer Center Prostate SPORE (Specialized Programs of Research Excellence), a 5-year, multidisciplinary, collaborative grant funded by the National Cancer Institute (NCI).

He was among the first to test chemotherapy agents at a time of general skepticism that chemotherapy would be useful in advanced prostate cancer. His research experience preceded the development of effective chemotherapy and extends to the current era of molecular targeted therapies and classification of cancer.

The addition of 2nd generation androgen-deprivation therapy (ADT) has resulted in an increased knowledge of androgen’s roll in prostate cancer. So, throughout the course of the prostate cancer, links have been developed even in areas where androgen was not previously thought to play a role.

This means the use of more therapies against prostate cancer such as bone targeted therapies, radiopharmaceuticals, immunotherapy, chemotherapy, and new ADT agents. The onslaught of new agents demands an understanding of how to optimize in combinations. In some settings combinations enhance each drug, but in others there is a negative effect. Logothetis goal is to create a new database, that will enable the physicians to know how and when to use these drugs effectively.

He received his medical degree from the University of Athens, Greece in 1974 and completed his internship and residency training at Cook County Hospital in Chicago.



  Comments: 1

  1. Kent Bragdon

    Hello. We would deeply appreciate meeting with you. I have stage 4 prostate cancer that has metastasized to my bones. I have heard and read many great things on you and your treatment. My PSA started at 165 and has gotten down to 12, but now is inching back up and is currently at a 26. I have done chemotherapy and hormone therapy. Please let me know if I could meet with you. Thank you!